Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Early Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Early Phase 1
1 (50.0%)Phase 2
1 (50.0%)Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
Phase 2
Recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Shandong Public Health Clinical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06709859
- Locations
- 🇨🇳
Shandong Public Health Clinical Center, Jinan, shangdong, China
IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer
Early Phase 1
- Conditions
- Advanced Primary Liver Cancer
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Shandong Public Health Clinical Center
- Target Recruit Count
- 12
- Registration Number
- NCT05411757
News
No news found